Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tamsulosin: an overview.

Christopher Chapple1, Karl-Erik Andersson

  • 1Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK. c.r.chapple@shef.ac.uk

World Journal of Urology
|May 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biology and Time Course of Obstruction-Induced Detrusor Underactivity Causing Postvoid Residual Urine.

International neurourology journal·2026
Same author

Bladder under stress: Pathological and adaptive shifts in channel expression.

Channels (Austin, Tex.)·2026
Same author

Erectile and Clitoral Dysfunction as Harbingers of Cardiovascular Disease: A Perspective.

Medicina (Kaunas, Lithuania)·2026
Same author

Endogenous vasopressin and vasopressin receptor 2 in bladder as anti-diuretic / anti-spasmodic targets for the treatment of multifactorial nocturia.

Continence (Amsterdam, Netherlands)·2026
Same author

12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia.

The Journal of urology·2025
Same author

Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study - Authors' reply.

Lancet (London, England)·2025

Tamsulosin is the leading alpha-blocker for benign prostatic hyperplasia (BPH). More rigorous studies are needed to compare BPH treatments effectively.

Area of Science:

  • Pharmacology
  • Urology
  • Clinical Medicine

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition in aging men.
  • Alpha-antagonists are a primary treatment modality for BPH symptoms.
  • Tamsulosin has emerged as a widely prescribed agent in this class.

Purpose of the Study:

  • To review the current clinical literature on tamsulosin.
  • To assess the existing evidence for tamsulosin in BPH treatment.
  • To identify gaps in the comparative effectiveness research for BPH therapies.

Main Methods:

  • Literature review of contemporary scientific articles.
  • Focus on clinical data and evidence related to tamsulosin.
  • Analysis of existing studies on BPH treatment agents.

Related Experiment Videos

Main Results:

  • Tamsulosin is the most frequently used alpha-antagonist for BPH.
  • The review highlights available clinical data supporting tamsulosin's use.
  • A significant lack of high-quality comparative studies was identified.

Conclusions:

  • Tamsulosin is a prominent treatment for benign prostatic hyperplasia.
  • Future research should prioritize randomized, placebo-controlled trials.
  • Robust comparative studies are essential for optimizing BPH management.